Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The aims of ZOLARMAB2 are fourfold. First, the investigators want to investigate if multiple
infusions of zoledronate can prevent the rebound activation of bone turnover and the
subsequent bone loss in patients previously treated with denosumab and if there is difference
between infusing zoledronate at fixed time-points after the last injection of denosumab or
when bone turnover is increased.
Second, the investigators want to investigate if bone loss will resume after controlling the
rebound activation of bone turnover during the first year after denosumab discontinuation and
if this can be prevented by yearly infusions of zoledronate.
Third, the investigators want to investigate the underlying pathophysiological mechanisms by
investigating biochemical markers, osteoclast and osteoblast activation signals in the bone
and bone marrow, and the pool of preosteoclasts/mature osteoclasts before and after treatment
with zoledronate.
Fourth, the investigators want to investigate the effect of denosumab discontinuation on
muscle mass and muscle strength and on insulin sensitivity.